Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 4.6% – What’s Next?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares fell 4.6% during trading on Friday . The stock traded as low as $9.80 and last traded at $9.87. 12,513,958 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 25,305,934 shares. The stock had previously closed at $10.35.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on RXRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp lowered their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

Recursion Pharmaceuticals Trading Down 10.3 %

The company has a 50 day moving average of $7.56 and a two-hundred day moving average of $7.02. The stock has a market capitalization of $3.63 billion, a PE ratio of -6.07 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals in the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the fourth quarter worth $26,000. Private Trust Co. NA acquired a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth $27,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.